Login to Your Account

Four-closure: Seelos deal with Ligand brings motley crew, hinges on financing

By Randy Osborne
Staff Writer

Thursday, September 22, 2016

Newly formed Seelos Therapeutics Inc. is "pretty well positioned to raise money," Ligand Pharmaceuticals Inc. President Matthew Foehr told BioWorld Today, and that's what Seelos needs to do in the four-piece licensing deal with San Diego-based Ligand.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription